Thazin Shwe, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn: Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. In: Experimental Gerontology. Band101, Januar 2018. Elsevier, 10. November 2017, S.13–36, doi:10.1016/j.exger.2017.10.029, PMID 29129736.Akzeptierte Entwurfsversion als Volltext. (PDF; 1,1 MB) 30. Oktober 2017, abgerufen am 23. August 2023 (englisch).
doi.org
Eva Morava: Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Minireview. In: Molecular Genetics and Metabolism. Band112, Ausgabe4, August 2014. Elsevier, 21. Juni 2014, S.275–279, doi:10.1016/j.ymgme.2014.06.002, PMID 24997537, PMC 4180034 (freier Volltext): „D-galactose has been safely used in clinical trials for FSGS in a dose of maximum 30g daily for a period of 4 months (20). […] No daily dose was used, however <sic!> above the suggested maximal intake of 50g/day (13). […] Based on our own and others’ experience D-galactose doses up to 50g/day seem to be safe.“
Martin Roser, Djuro Josic, Maria Kontou, Kurt Mosetter, Peter Maurer: Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids. In: Journal of Neural Transmission. Band116, Nr.2, 1. Februar 2009, S.131, doi:10.1007/s00702-008-0166-9.
Melita Salkovic-Petrisic, Jelena Osmanovic-Barilar, Ana Knezovic, Siegfried Hoyer, Kurt Mosetter: Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin. In: Neuropharmacology. Band77, S.68–80, doi:10.1016/j.neuropharm.2013.09.002.
Eric De Smet, Jean-Philippe Rioux, Hélène Ammann, Clément Déziel, Serge Quérin: FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Fallbericht. In: Nephrology, Dialysis, Transplantation. Band24, Ausgabe9, September 2009. Oxford University Press, 9. Juni 2009, S.2938–2940, doi:10.1093/ndt/gfp278, PMID 19509024 (englisch, Volltext [PDF; 142kB; abgerufen am 22. August 2023]).
Matjaž Kopač, Anamarija Meglič, Rina R. Rus: Partial remission of resistant nephrotic syndrome after oral galactose therapy. Fallbericht. In: Therapeutic Apheresis and Dialysis. Band15, Ausgabe3, Juni 2011. Wiley, 30. Mai 2011, S.269–272, doi:10.1111/j.1744-9987.2011.00949.x, PMID 21624074 (englisch, wiley.com).
Thazin Shwe, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn: Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. In: Experimental Gerontology. Band101, Januar 2018. Elsevier, 10. November 2017, S.13–36, doi:10.1016/j.exger.2017.10.029, PMID 29129736.Akzeptierte Entwurfsversion als Volltext. (PDF; 1,1 MB) 30. Oktober 2017, abgerufen am 23. August 2023 (englisch).
nih.gov
ncbi.nlm.nih.gov
Eva Morava: Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Minireview. In: Molecular Genetics and Metabolism. Band112, Ausgabe4, August 2014. Elsevier, 21. Juni 2014, S.275–279, doi:10.1016/j.ymgme.2014.06.002, PMID 24997537, PMC 4180034 (freier Volltext): „D-galactose has been safely used in clinical trials for FSGS in a dose of maximum 30g daily for a period of 4 months (20). […] No daily dose was used, however <sic!> above the suggested maximal intake of 50g/day (13). […] Based on our own and others’ experience D-galactose doses up to 50g/day seem to be safe.“
Eric De Smet, Jean-Philippe Rioux, Hélène Ammann, Clément Déziel, Serge Quérin: FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Fallbericht. In: Nephrology, Dialysis, Transplantation. Band24, Ausgabe9, September 2009. Oxford University Press, 9. Juni 2009, S.2938–2940, doi:10.1093/ndt/gfp278, PMID 19509024 (englisch, Volltext [PDF; 142kB; abgerufen am 22. August 2023]).
Matjaž Kopač, Anamarija Meglič, Rina R. Rus: Partial remission of resistant nephrotic syndrome after oral galactose therapy. Fallbericht. In: Therapeutic Apheresis and Dialysis. Band15, Ausgabe3, Juni 2011. Wiley, 30. Mai 2011, S.269–272, doi:10.1111/j.1744-9987.2011.00949.x, PMID 21624074 (englisch, wiley.com).
Thazin Shwe, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn: Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. In: Experimental Gerontology. Band101, Januar 2018. Elsevier, 10. November 2017, S.13–36, doi:10.1016/j.exger.2017.10.029, PMID 29129736.Akzeptierte Entwurfsversion als Volltext. (PDF; 1,1 MB) 30. Oktober 2017, abgerufen am 23. August 2023 (englisch).
oup.com
academic.oup.com
Eric De Smet, Jean-Philippe Rioux, Hélène Ammann, Clément Déziel, Serge Quérin: FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Fallbericht. In: Nephrology, Dialysis, Transplantation. Band24, Ausgabe9, September 2009. Oxford University Press, 9. Juni 2009, S.2938–2940, doi:10.1093/ndt/gfp278, PMID 19509024 (englisch, Volltext [PDF; 142kB; abgerufen am 22. August 2023]).
